@article{95e8f16585bf4422b1e24a802673f598,
title = "Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: Final results of the NCRI CLL210 trial",
note = "Funding Information: 1University of Liverpool, Liverpool; 2Clatterbridge Cancer Center NHS Foundation Trust, Liverpool; 3University of Birmingham, Birmingham; 4Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool; 5The Royal Bournemouth Hospital, Bournemouth; 6The Christie NHS Foundation Trust, Manchester; 7Churchill Hospital, Oxford; 8Southampton General Hospital, Southampton; 9Royal Marsden NHS Foundation Trust, Sutton; 10University Hospital of Wales, Cardiff; 11Leicester Royal Infirmary, Leicester; 12City Hospitals Sunderland NHS Trust, Sunderland; 13Nottingham University Hospitals NHS Trust, Nottingham and 14University of Leeds, Leeds, UK Correspondence: ANDREW R. PETTITT - arp@liv.ac.uk doi:10.3324/haematol.2019.230805 Acknowledgments: we are grateful to Cancer Research UK for endorsing the study, to the NIHR for supporting local trial delivery, and to industry partners for funding trial co-ordination (Celgene, Chugai) and providing (Celgene, GSK/Novartis) or subsidising (Baxter, Chugai) investigational medical products.",
year = "2020",
month = dec,
doi = "10.3324/haematol.2019.230805",
language = "English",
volume = "105",
pages = "2868--2871",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",
}